Company name Proteostasis Therapeutics, Inc.
Stock symbol PTI
Status Under Investigation

NEW YORK, March 21, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Vuzix Corporation (NASDAQ: VUZI).

Our investigation concerns whether Proteostasis has violated the federal securities laws and/or engaged in other unlawful business practices.

On March 20, 2018, Kerrisdale Capital Management published a report entitled “Proteostasis Therapeutics, Inc.: Hyped-Up Lung Data? Just a Lot of Hot Air.”  The report asserted that in the Phase 2 study for the Company’s cystic-fibrosis drug, PTI-428, “the placebo group’s small size and anomalously bad outcomes misleadingly make the treatment group’s unimpressive results look good by comparison.”  The report concluded that the drug “is ineffective and will likely fail future Phase 3 trials.”

Following this news, the share price of Proteostasis fell $1.83 per share, or over 26%, to close at $5.16 on March 20, 2018.

If you purchased or otherwise acquired Proteostasis shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?

Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.